The safe parameters for citrate anticoagulation during the continuous renal replacement therapy in patients after cardiac surgery were determined in retrospective analysis of 86 clinical cases. The clinical and biochemical variables and hemostasis parameters were investigated, bleeding occurrence and drainage losses were evaluated. The absence of significant differences with heparin anticoagulation were noted. The increase of liver failure markers within 48 h of undergoing procedure were detected, the drainage losses volume were significantly less during citrate anticoagulation. In conclusion, the safety and efficacy of citrate anticoagulation in patients at high risk of bleeding in the postoperative period were detected, but with limited clinical usage in case of multiple organ dysfunction.
